NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria

    HELSINGBORG, Sweden, Nov. 30 /CNW/ - NOLabs AB, the Swedish medtech
company developing innovative nitric oxide-containing medical devices based on
the NitroSense(R) Technology, today reported that it has achieved another
important milestone in the development of a new line of products for wounds
infected by MRSA-bacteria. MRSA stands for Methicillin Resistant
Staphylococcus aureus, a bacterium that is particularly troublesome in
hospital-acquired infections due to its resistance to several traditional
    In experiments performed at the Malmoe University Hospital in Sweden,
researchers showed that NOLabs' technology has a promising ability to kill a
wide range of pathogens, including MRSA.
    According to the US Centers for Disease Control and Prevention 126,000
hospitalisations are related to MRSA and 19,000 deaths are associated with
serious MRSA infections every year in U.S. hospitals. Patients at risk for
infection with MRSA include those with severe disease, recent surgery or
indwelling medical devices, such as urinary catheters.
    Goran Beijer, CEO of NOLabs says: "The recent results show that we are on
the right track towards products with an enormous potential globally. The
anti-microbial effect of NO will be key in several products that will prevent
and/or treat infection depending on dosing. We are now accelerating our
development program and expect to have the first products on the market during
    NOLabs' NitroSense(R) Technology assures controlled, local delivery of
pure nitric oxide in a well-defined concentration range during a well-defined
time period. The main areas are prevention of catheter related urinary tract
infections, relief of neuropathic pain and wound care products with an
anti-bacterial effect.
    For more information please visit our home page:

    NOLabs is a Swedish medtech company developing and marketing nitric
oxide-containing medical devices for various medical applications. Nitric
oxide is a natural substance, produced by the human body. Its physiological
effects include the control of local blood supply and the protection against
microbes. In particular, NOLabs focuses on prevention of infection and pain
relief for patients suffering from diabetes-related complications such as
chronic wounds and neuropathic pain. Another focus area is the prevention and
treatment of catheter-associated urinary tract infections. NOLabs has
developed the innovative, cost efficient and highly effective NitroSense(R)
Technology with a significant potential to address serious health issues that
impact the lives of over 100 million people.

For further information:

For further information: Goran Beijer, E-mail,
Phone: +46-42-33-65-22; Susanne Goransson, E-mail:, Phone: +46-42-33-65-30

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890